- 1 Reevaluating the Role of ACE Inhibitors in Skin Fibrosis Risk: Evidence from
- 2 Mendelian Randomization
- 3 Running title: ACEI does not decrease skin fibrosis
- 4 Yangyang Wei^{1,2,*}, Ziqi Wan^{2,*}, Yiwen Jiang², Zhengye Liu³, Ming Yang^{4,#}, Jieying
- 5 $Tang^{1,\#}$
- 6 1. Department of Plastic Surgery, Beijing Tsinghua Changgung Hospital, School of
- 7 Clinical Medicine, Tsinghua University, Beijing, China.
- 8 2. Eight-year Program, Peking Union Medical College and Chinese Academy of
- 9 Medical Sciences, Beijing, China.
- 10 3. Department of Plastic and Aesthetic Center, The First Affiliated Hospital, School of
- 11 Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
- 12 4. Department of Cardiology, Peking Union Medical College Hospital, Chinese
- 13 Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
- 14
- 15 ^{*}Contributed equally
- [#]Corresponding authors: Dr. Jieying Tang, Department of Plastic Surgery, Beijing
- 17 Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University,
- 18 Beijing, China. Tel: 8613811271136. Email: tjya01274@btch.edu.cn
- 19 Dr. Ming Yang, Department of Cardiology, Peking Union
- 20 Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union
- 21 Medical College, Beijing, China. Tel: 86-10-69155005. Email: yangming@pumch.cn
- 22
- 23 **Fund:** Beijing Tsinghua Changgung Hospital Fund (Grant No. 12023C1004)
- 24
- 25 Interest Statement
- 26 All of us declare that we have no competing interests.
- 27
- 28 Ethical Approval
- 29 Not Applicable.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 30

31 Ethnic Statement

- 32 Not Applicable.
- 33

34 Data Availability Statement

- 35 Sources of full summary GWAS datasets were listed in Supplementary File 2. No new
- 36 data was generated from recurrent study.
- 37

38 Author Contributions

39 Conceptualization: The study was initially conceptualized by YW, ZW and JT. They

- 40 developed the research idea and designed the overall framework of the study.
- 41 Methodology: Methodology was developed by ZW, YJ and ZL. They were 42 responsible for designing and implementing the experimental protocols.
- 43 Investigation: Investigation and data collection were primarily conducted by YW, ZW
- 44 and JT. They carried out the experiments and gathered the necessary data.
- 45 Data Analysis: Data analysis was performed by YW and ZW. They processed the raw
- 46 data and conducted the statistical analyses.
- 47 Writing Original Draft Preparation: The original draft of the manuscript was written
- 48 by YW and ZW. They prepared the initial version of the paper, including the 49 introduction, methods, results, and discussion sections.
- 50 Writing Review & Editing: Review and editing of the manuscript were conducted by
- 51 YJ, ZL, MY and JT. They reviewed the draft for important intellectual content and 52 made revisions.
- Funding Acquisition: Funding for the study was secured by MY and JT. They appliedfor and obtained the necessary grants to support the research.
- 55 Supervision: Supervision of the entire project was provided by MY and JT. They 56 oversaw the project progress and provided guidance throughout the research.
- 57 Project Administration: Project administration, including coordination of research
- 58 activities and maintaining timelines, was managed by MY and JT.
- 59

60 Manuscript Count: 3862

61 Figure count: 4, Table count: 7

62

63 Abstract:

64 Background: Skin fibrosis, characterized by excessive extracellular matrix 65 deposition, leads to hypertrophic scars and keloids, which are both common and often 66 detrimental conditions. Angiotensin-converting enzyme (ACE) inhibitors have shown 67 promise in animal studies and limited clinical trials for reducing scar formation. 68 However, the causal relationship between ACE inhibition and skin fibrosis remains 69 unclear.

Methods: This study employed two-sample Mendelian randomization (MR) analysis to investigate the causal effect of ACE inhibition on skin fibrotic diseases. We utilized genetic variants associated with serum ACE levels, ACE inhibition, and effect of decreasing blood pressure by ACE inhibition as instrumental variables. We analyzed the association between these exposures and the incidence of skin fibrosis, hypertrophic scars, and keloids using various MR methods.

Results: We found no significant causal relationship between genetically proxied serum ACE levels, or local skin tissue ACE expression and the risk of skin fibrosis, hypertrophic scars, or keloids. Additionally, there was no direct causal relationship between the effect of ACE inhibitors on blood pressure reduction and the risk of skin fibrotic diseases. However, we observed a significant negative association between systolic blood pressure (SBP) and the risk of hypertrophic scars. Conversely, we found a positive association between β -blockers and the risk of skin fibrosis.

Conclusion: Our findings suggest that ACE inhibitors do not have a direct causal
effect on the risk of skin fibrotic diseases, including hypertrophic scars and keloids.
This challenges the potential of ACE inhibitors as a therapeutic option for preventing
or treating these conditions.

87

88 Keywords: skin fibrosis, angiotensin-converting enzyme, Mendelian Randomization

89

90 Introduction

91 Skin fibrosis involves the deposition of extracellular matrix of dermis, a process that can occur in all kinds of wound healing of injuries.¹ Hypertrophic scars and keloids 92 93 are two common types of excessive scar caused by skin fibrosis. Hypertrophic scar is 94 that scar proliferation stays within the limits of the edges of the initial scar, whereas 95 keloid is characterized by pseudo-tumor proliferation extending over the edges of the initial wound.^{1,2} These conditions are highly prevalent in population, affecting 96 patients with all kinds of skin wounds including surgical ones. Excessive scars can 97 98 lead to unexpected changes in appearance, causing pain and functionally impairing 99 patients' quality of life. Current conservative treatments for excessive scarring include cryotherapy, corticosteroid injections or tapes, chemotherapy and surgery.¹ Few 100 101 interventions target the molecular mechanism specifically. Mechanisms of skin 102 fibrosis are not completely understood, involving intricate pathways such as inflammatory reactions and hormone regulation.³ 103

104 Angiotensin-converting enzyme (ACE) is a well-known molecule that can increase 105 blood pressure by converting angiotensin I to angiotensin II within renin-angiotensin system (RAS).⁴ Angiotensin II can bind to the Type I angiotensin receptor (AT1 106 107 receptor) and initiate the complex downstream effects. The serum ACE has been 108 demonstrated to be critical in the development and progression of fibrosis in multiple organs, including heart, liver, and kidney. ⁵⁻⁹ Effects of angiotensin II include the 109 110 increase of collagen and fibronectin synthesis, which are ultimately associated with 111 fibrosis in different organs. Given its pivotal role in the regulation of RAS, ACE has 112 been inferred to be a therapeutic potential target for skin fibrosis due to its effects on inflammatory reaction and homeostasis of skin healing.⁵ Animal studies have 113 114 provided evidence that ACE gene deficiency decreases scar formation in rats effectively. ^{11,12} A study on rabbits also demonstrated that oral ACE inhibitor 115 (Enalapril) effectively decreased hypertrophic scars on rabbit ears. ¹³ And several 116 117 clinical researches reported the effectiveness of ACE inhibitors in decreasing the 118 formation of excessive scars. A retrospective chart review study on bilateral breast 119 reduction surgery (n = 961) discovered patients with an ACE inhibitors or angiotensin 120 receptor blocker (ARB) exhibited a significantly lower incidence of being diagnosed 121 as hypertrophic scar. ¹⁴ Furthermore, in another double-blind clinical trial conducted 122 in Iran population (n = 30), patients treated with local topical Enalapril exhibited 123 hypertrophic scars with significantly smaller mean thickness than the placebo-treated 124 ones, along with a significantly lower mean itching score. ¹⁵ However, the sample 125 sizes of the clinical trial were insufficiently large and only involved Iran population. 126 The researches were limited by study design. ¹⁶

Mendelian randomization is a method to explore the causal effect of two traits 127 (exposure and outcome) via genetic instrumental variants (IVs). ^{17, 18} It holds three 128 assumptions: 1) IVs are extensively associated with exposure; 2) There are no 129 130 confounders between the instruments and outcome; 3) IVs' effect on outcome can 131 only be exerted via exposure. MR provides a convenient method for exploring the 132 causal relationship between phenotypes with evidence of nearly the same level as 133 randomized controlled trial (RCT) when conducting RCTs is challenging. However, 134 there has not been an exploration of the causal relationship between ACE inhibition 135 and diseases related to skin fibrosis using MR analysis.

Here we aimed to explore the causal effect of ACE inhibitors (ACEi) on excessive scars related to skin fibrosis, including hypertrophic scar and keloids, by two-sample MR analysis from multiple dimensions. We investigated the causal effects of genetically proxied serum ACE, inhibition of ACE and systolic and diastolic blood pressure (SBP/DBP), respectively, on the incidence of skin fibrosis. And we further explored the causal effects of SBP, DBP, β blockers and calcium channel blockers, angiotensin receptor blockers and excessive scarring related to skin fibrosis.

143

144 Methods

145 Study design

The study design is illustrated in Figure 1. To investigate the causal effect of ACE inhibitors on skin fibrotic diseases, we conducted MR analysis with exposures of serum ACE, genetically-proxied inhibition of serum ACE, and effect of increasing SBP and DBP by ACE, respectively. Furthermore, we employed Summary-based MR 150 analysis (SMR) to explore the causal effect of ACE expression in local skin tissue on 151 skin fibrotic diseases. Considering that the target of Type 1 angiotensin II receptor 152 blockers (ARBs), AT1 receptor is the main downstream receptor of angiotensin II, we 153 investigated causal relationship between ARBs and skin fibrotic diseases. Moreover, considering that blood pressure might be a risk factor of skin fibrotic diseases ^{19, 20}, in 154 order to investigate whether the effect of ACE on skin fibrotic diseases is through the 155 156 blood pressure, we also investigated the causal effect of blood pressure and targets of 157 other anti-hypertension drugs (ß blockers and calcium channel blockers, abbreviated 158 as BBs and CCBs) on skin fibrotic diseases through MR analysis. All the genetic IVs were chosen on autosomes in order to avoid sex-specific effects.²¹ 159

160 Data sources

For serum ACE concentration, we initially utilized single SNP "rs4343" as IV of 161 serum ACE. Rs4343 is located in the ACE gene, which is extensively associated with 162 an indel known as Alu in the 16th intron and then associated with expression of ACE. 163 23 Rs4343 exhibits the strongest association with serum ACE inhibition (p = 1.53e-213) 164 among SNPs according to the group of IV proxied serum ACE inhibition.²⁴ 165 166 Additionally, we utilized another group of IVs from a protein quantitative trait locus 167 (pQTL) research of serum ACE of 35,275 individuals with Island ancestry. The population shares a similar age, gender, and BMI structure with the UKB corhort.²² 168 169 Furethermore, in order to supply more evidence of the causal relationship between 170 serum ACE inhibition and skin fibrotic diseases, we utilized a group of IVs (including 171 rs4343) to proxy serum ACE inhibition from a previous MR study, which was from a 172 pQTL of 4,174 individuals from Genetic Epidemiology Research on Adult Health and Aging.²⁴ 173

We initially employed single SNP "rs4291" to proxy the effect of ACE inhibition on decreasing SBP. Rs4291 is located on the promoter of ACE gene, which is also extensively associated with the indel *Alu* and exhibits the most significant correlation with the effect of ACE inhibition on decreasing SBP. ²⁵ Its effect was from a meta-analysis of GWAS covered 757,601 individuals with European ancestry of UKB individuals and International Consortium of Blood Pressure GWAS. ²⁶ Then we

180 utilized another group of IV associated with the decrease effect of SBP by ACE (containing 2 SNPs) extracted by a previous MR study, whose effect was from the 181 mentioned meta-analysis covered 757,601 individuals.²⁴ We accessed GWAS data of 182 SBP and DBP from a previous study encompassing 469,767 and 490,469 individuals 183 within European ancestry in UK Biobank cohort.²⁸ And we selected SNPs that have 184 strong relevance (p < 5e-8) with serum ACE according to the mentioned pQTL, and 185 186 extracted their effects on SBP or DBP from these two GWAS datasets of SBP and 187 DBP. From this set of SNPs, we further included SNPs that also had strong relevance of SBP or DBP (p < 5e-6) to proxy the ACE-induced increase of SBP or DBP. 188

For local expression of *ACE* gene in skin tissue, summary data of expression quantitative trait locus research (eQTL) of local tissue was downloaded from GTEx v8 data. ²⁹ Considering the influence of sunshine exposure on skin, we employed summary data from suprapubic skin and skin of lower leg to represent skin with and without sunshine exposure respectively.

194 In order to investigate the potential causal effect of anti-hypertension drugs (BBs and 195 CCBs) on skin fibrotic diseases, we extracted IVs proxied the effect of increasing SBP 196 by BB and CCB drug target gene (ADRB1 for BB, CACNA1D, CACNA1F, 197 CACNA2D1, CACNA2D2, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, CACNG1, and CACNA1C for CCB) from a previous study of MR analysis. ²⁶ IV for 198 199 effect of decreasing SBP by ARBs target gene (type 1 angiotensin II receptor, AT1) were extracted from another MR study. ²⁷ All the effect data to SBP was from the 200 201 meta-analysis of GWAS covered 757,601 individuals All the detailed information for 202 exposures were listed in Table 1.

We employed GWAS datasets for hypertrophic scar, keloid, skin fibrosis, and scar condition (defined as a fibrotic scar that could not be differentiated as keloid or hypertrophic scar). ¹ All the data were sourced from populations of European ancestry. Among these data for hypertrophic scar and one data of skin fibrosis and scar condition were from FinnGen, whereas data for keloid and the other data of skin fibrosis and scar condition were from UK Biobank. The detailed information for each dataset was listed in Table 2. ^{28, 30}

210 MR IVs selection

211 For IVs of multiple SNPs proxied effects of target genes (ACE, target genes for BBs, 212 CCBs and ARBs), we selected SNPs with strong relevance (p < 5e-8) to respective 213 exposures. For serum ACE and serum ACE inhibition, we selected SNPs within ± 100 214 kb of ACE gene. For effects of decreasing SBP by BBs and CCBs, we selected SNPs within corresponding genes or in the promoters and enhancers. ²⁶ IV for ARB was 215 216 selected in the drug-targeted genes associated with BP at a genome-wide significant level, which was identified in DrugBank.²⁷ Promoter and enhancer regions of 217 218 corresponding drug targets were identified using the GeneHancer database in the 219 GeneCards online platform. Subsequently, we decreased the linkage disequilibrium of the IVs by clumping on condition that genetic distance > 10,000 kb and $r^2 < 0.1$. 220

From the GWAS data of SBP and DBP, we selected SNPs with strong relevance (p < 5e-8). ³¹ Then SNPs was clumped on condition that genetic distance > 10,000 kb and $r^2 < 0.0001$ to eliminate linkage disequilibrium.

For IV of effect of serum ACE on decreasing SBP and DBP, we extracted SNPs with extensive relevance for serum ACE (data from pQTL of serum ACE, p < 5e-8) and SBP or DBP (data from GWAS of SBP and DBP, p < 5e-6, for no SNP existed on condition that p < 5e-8). Then we selected SNPs within \pm 100 kb of ACE gene and clumped on condition that genetic distance > 10,000 kb and r² < 0.1 thereby reducing linkage disequilibrium.

230 For all IVs that will be used in MR analysis, we harmonized effects of SNPs on 231 exposure and outcome to ensure effects relative to the same allele and exclude 232 palindromic SNPs with intermediate allele frequencies (> 0.42). In order to avoid 233 potential confounding, we delete SNPs strongly related (p < 5e-8) to outcomes (skin fibrosis, hypertrophic scar and keloid) by investigating all the SNPs on PhenoScanner 234 database (http://www.phenoscaner.medschl.cam.ac.uk/) . ³² For the exposure of SBP, 235 DBP and the effect on SBP/DBP by ACEi, ARB, BBs and CCBs included UKB 236 237 cohorts, MR analysis with sample overlapping (outcome data from UKB cohorts) was 238 eliminated by checking the sample sources of exposures and outcomes from different 239 cohorts.

240 Statistics

241 R (Version 4.3.3, The R Foundation for Statistical Computing Platform, Vienna, Austria) was used to perform MR analysis and subsequent sensitivity analysis. R 242 packages "dplyr", "TwoSampleMR" (Version 0.6.4) and "ieugwasr" ³³ were used to 243 input, clump and analyze data. To explore the causal relationship of exposures and 244 245 outcomes, when only one SNP existed in IV, we used method Wald ratio, while when two or more SNPs existed, we used method inverse variance weighted (IVW) 246 including random effects IVW (IVW-MRE) and fixed effects IVW (IVW-FE). ³⁴ In 247 order to obtain more reference, we performed MR analysis by the weighted-median³⁵, 248 MR Egger ³⁶, simple-mode and weighted-mode method as secondary analysis 249 250 methods. In MR analysis between drug targets (ACEi, ARBs, BBs and CCBs), we 251 didn't employ the MR Egger due to the confounding effects of IVs against the 252 INSIDE assumptions of MR Egger. Cochran's Q statistic was used to estimate the 253 heterogeneity of IVs. If no significant heterogeneity exists (pQ < 0.05), we referred to results from the fixed-effects IVW MR analysis. If significant heterogeneity exists 254 255 (pQ < 0.05), we referred to results from the random-effects IVW MR analysis. And 256 we tested the pleiotropy of SNPs by the intercept value from the MR Egger method ³⁶⁻³⁸. The p value less than 0.05 indicated significant pleiotropy. If IVs of exposure 257 258 were with pleiotropy, the analysis results would be excluded. F statistics were used to evaluate the risk of weak instrument bias. We used formula that $F = (N-k-1)/k*r^2/(1-r^2)$ 259 260 to calculate F. Among those N is the sample size of GWAS research, k is the amount of IVs. For each IV, r^2 was calculated as $2*MAF*(1-MAF)*\beta^2$. ³⁹ If F statistics of a 261 262 group of IVs was above 10, we considered that risk of weak instrument bias of IV can 263 be ignored. An online tool (https://sb452.shinyapps.io/power/) was used to calculate the statistical power for MR analysis. 40 264

Summary-based MR (SMR) analysis was conducted on SMR software (version 1.3.1 for Windows system) developed by Zhang et al. ⁴¹ The software extracted SNPs within \pm 5 Mb of ACE gene and with significant relevance of ACE expression in specific tissue (p < 5e-8) from the two eQTL datasets from skin tissue. We excluded SNPs whose allele frequency below 0.01. Then we reduced LD (R² < 0.1) by referring

270 to the 1000G European data. GWAS datasets of skin fibrotic diseases were used as

- 271 outcomes in SMR test. Then we conducted HEIDI test to test the heterogenesis. If
- pHEIDI was above 0.05, we considered the IVs exhibit no significant heterogenesis.
- 273 Results of SMR with significant heterogenesis were removed.
- 274

275 **Results**

276 IVs selection

All the F statistics of IVs were above 10 (listed in Table 1), and the explained variance of IVs were R^2 of 0.025% to 39%. Detailed information including amounts of SNPs, R^2 , F statistics, sample size and source were shown in Table 1. All the SNPs used in MR were listed in Supplementary File 1. MR analysis whose exposure and outcome were with sample overlapping was removed.

282 Effect of serum ACE or ACE inhibition and skin fibrotic diseases

283 Our analysis of MR results revealed little causal relationship between serum ACE or 284 ACE inhibition and skin fibrotic diseases. For single SNP (rs4343) proxied serum 285 ACE inhibition, results of Wald ratio showed little causal effect on skin fibrotic diseases (hypertrophic scar: OR = 1.04, 95% CI 0.93-1.17, p = 0.46; keloid: OR = 1.12, 286 287 95%CI 0.83-1.52, p = 0.45; skin fibrosis and scar condition from UKB: OR = 0.95, 288 95%CI 0.39-2.35, p = 0.30; skin fibrosis and scar condition from FinnGen: OR = 0.93, 289 95% CI 0.81-1.07, p = 0.29). For IVs composed of multiple SNPs proxied serum ACE, 290 results of IVW showed little causal effect on skin fibrotic diseases (hypertrophic scar: 291 OR = 0.96, 95% CI 0.86-1.07, p = 0.44; keloid: OR = 1.03, 95% CI 0.78-1.35, p = 0.49; 292 skin fibrosis and scar condition from UKB: OR = 0.98, 95% CI 0.90-1.06, p = 0.56; 293 skin fibrosis and scar condition from FinnGen: OR = 1.11, 95% CI 0.98-1.25, p =294 0.12). For IVs containing multiple SNPs proxied serum ACE inhibition, we found 295 little causal effect of ACE inhibition on skin fibrotic diseases (hypertrophic scar: OR 296 = 0.998, 95% CI 0.924-1.078, p = 0.96; keloid: OR = 1.05, 95% CI 0.85-1.29, p = 0.66; 297 skin fibrosis and scar condition from UKB: OR = 0.97, 95%CI 0.91-1.03, p = 0.33; 298 skin fibrosis and scar condition from FinnGen: OR = 0.94, 95%CI 0.85-1.03, p = 299 0.16). Additionally, other methods also showed little causal relationship between

serum ACE or ACE inhibition and skin fibrotic diseases. No significant pleiotropy or
heterogeneity bias was observed in these MR analysis (shown in Table 3).

302 Effect of blood pressure by ACE or ACE inhibition and skin fibrotic diseases

For both IVs of single SNP or multiple SNPs, results of Wald ratio and IVW-FE showed little causal association between the effect of ACE inhibition on decreasing blood pressure by on skin fibrotic diseases (hypertrophic scar, skin fibrosis and scar condition), all the p values were above 0.05 (shown in Table 4 and Figure 2). For MR analysis with IVs containing 2 SNPs, heterogeneity tests showed no significant heterogenetic bias existed in MR analysis (shown in Table 4).

309 Local ACE expression and skin fibrotic diseases

For skin tissue exposed to or shielded from sunshine exposure, 8 and 11 SNPs was extracted from Qtex datasets respectively to proxy local ACE expression, respectively. Notably, all the p values of SMR analysis were above 0.05 (shown in Table 5), which showed that little causal effect of ACE expression in local skin tissue on susceptibility of skin fibrotic diseases, irrespective of sunshine exposure. All the p values for HEIDI test were above 0.05 (shown in Table 5), which revealed that no significant heterogenetic bias existed.

317 Systolic and diastolic blood pressure and skin fibrotic diseases

318 Results of IVW-FE method showed significant negative causal effects of SBP on 319 hypertrophic scar (OR = 0.69, 95% CI 0.54-0.89, p = 0.004). Similarly, results of MR 320 Egger method, and IVW-MRE also demonstrated negative causal effect of SBP on 321 hypertrophic scar, (MR Egger: OR = 0.480, 95% CI 0.244-0.947, p = 0.035; 322 IVW-MRE: OR= 0.69, 95% CI 0.53-0.90, p = 0.007). These results collectively 323 indicated that higher SBP level is causally associated with reduced risk of developing 324 hypertrophic scar. However, IVW and other methods indicated little causal effect of 325 DBP on hypertrophic scar. Additionally, no significant causal relationship was found 326 between SBP or DBP and skin fibrosis and scar condition (shown in Table 6 and 327 Figure 3). Sensitivity tests showed no obvious bias in pleiotropy and heterogenity.

328 Effect of other antihypertension drugs and skin fibrotic diseases

329 Results of IVW-FE revealed obvious positive causal relationship between effect of

330 BBs on decreasing SBP and skin fibrosis and scar condition from FinnGen (OR =331 1.184, 95% CI 1.033-1.357, p = 0.015), which indicated that BBs caused an increase 332 of risk of skin fibrosis. Heterogeneity and pleiotropy tests for both MR analysis 333 showed little heterogeneity and horizontal pleiotropy (shown in Table 7 and Figure 4). 334 However, results of IVW-MRE indicated little causal relationship between effect of 335 BBs on decreasing SBP and hypertrophic scar, for which heterogenesis test revealed 336 significant heterogeneity of this result (pQ = 0.008). And results of IVW-FE showed 337 little causal relationship between effects of CCBs on decreasing SBP and hypertrophic 338 scar or skin fibrosis and scar condition, either. Similarly, results of simple mode, weighted mode and weighted median methods for MR analysis showed similar 339 340 conclusions of the little causal effect of CCBs on hypertrophic scar or skin fibrosis 341 and scar condition. In heterogeneity and pleiotropy test, except MR between BBs and hypertrophic scar, no obvious pleiotropy and heterogeneity bias was observed. Wald 342 343 ratio results found little causal relationship between blood decreasing effect of ARBs 344 and skin fibrotic diseases (shown in Table 7 and Figure 4).

345

346 Discussion

Our study found little causal relationship of ACE inhibition on skin fibrotic diseases using two sample MR approach. None of serum ACE, effect of decreasing SBP/DBP by ACE inhibition or local expression of ACE gene in skin tissue was discovered significant with causal association with the occurrence of skin fibrosis and excessive scars including keloid and hypertrophic scar.

352 Nevertheless, a limited number of animal studies have suggested that ACE inhibitors 353 can impede progression of fibrotic skin scars when administered orally or topically, indicating their potential as a therapeutic or preventive agent for such scars.¹¹⁻¹³ 354 Additionally, a few case reports, ⁴³ the aforementioned retrospective study ¹⁴ reported 355 the potential of ACE inhibitor drugs (Enopril and Captopril) treatments for 356 357 hypertrophic scar and keloid on patients. However, the isolated case reports and 358 retrospective study did not exclude disrupting factors. Moreover, in the retrospective 359 study, utilization of ACE inhibitor and ARB were mixed and the dosage were not 360 unified. The aforementioned clinical trial conducted in Iran¹⁵ demonstrated the 361 effectiveness of tropical ACE inhibitor (Enopril) on decreasing the size of 362 hypertrophic scar. However, there was a lack of large scale clinical researches covered 363 multiple populations which provided evidence for the efficacy of ACE inhibitors in 364 prevention or treatment of skin fibrotic scars.

365 A potential explanation for the discrepancies in the findings lies in the diverse 366 statistical criteria employed to define the outcomes. While animal studies and clinical 367 trials assessed the outcomes based on scar area, our research utilized a GWAS dataset with a binary outcome measure. Our findings indicated that ACE inhibition does not 368 decrease the incidence of skin fibrotic diseases, which is not conflictive with the 369 370 conclusion that ACE inhibitors have potential to diminish the size of skin fibrotic scar. 371 To the best of our knowledge, there are no quantitative GWAS datasets available with 372 phenotype specially focused on the size of fibrotic scar.

Furthermore, the regulation of fibrotic proliferation in tissue by ACE is not a 373 374 unidirectional process. The products of ACE, angiotensin II, exhibits dual effects on 375 fibrosis. When angiotensin II bind to AT1 receptor, its downstream effect is to 376 promote fibrosis by promoting inflammation reactions such as TGF-B synthesis. 377 When angiotensin II binding to AT2 receptor, it can counteract inflammation reactions 378 and suppress reactions like TGF- β synthesis. Additionally, other downstream products 379 of angiotensin II, such as angiotensin III and angiotensin IV, also have the potential to inhibit fibrosis. 44, 45 380

It is noted that the expression of AT1 receptors in skin is comparatively low. RNA seq from normal tissue of different organs indicated that reads per kilobase per million mapped reads (RPKM) of AT1 receptor in skin is 0.906 \pm 0.285, significantly lower than that in other tissues such as liver (21.967 \pm 2.326), kidney (5.741 \pm 1.363) and heart (2.423 \pm 1.416). ⁴⁶ These results prompt that the regulation effect by ACE in skin might be less pronounced than that in other tissue or organs.

387 Compared to previous studies, our research had several advantages: 1) Our study 388 provided an exploration of the association between ACE and skin fibrotic diseases 389 with a larger sample scale in European population. 2) Our study design had

advantages of eliminating confounding factors as much as possible by pleiotropy test
and LD diminishing. 3) Our study investigated the causal relationship beyond merely
association relationship by the method of MR analysis.

393 Our research also existed some limitations. The conclusion that ACE inhibition has 394 little causal effect on skin fibrosis was not fully confirmed due to several limitations: 1) All the MR analysis were conducted within a single population of European 395 396 descent. To validate the effect of ACE inhibition on skin fibrotic diseases in other 397 population, GWAS researches from corresponding population were required. 2) The 398 statistical power of MR was insufficient, necessitating GWAS studies of skin fibrotic diseases with larger sample sizes. To the best of our knowledge, exposures for effect 399 400 of BBs, CCBs and ARBs lacked data of pQTLs of corresponding protein targets, and 401 the analysis primarily included the effects of decreasing blood pressure. Consequently, 402 the direct effects of those protein targets require further research to determine whether 403 significant causal relationship exists between their effects and skin fibrotic diseases.

404

405 **Conclusion**

406 Our findings suggest that ACE inhibitors do not have a direct causal effect on the risk 407 of skin fibrotic diseases, including hypertrophic scars and keloids. This challenges the 408 potential of ACE inhibitors as a therapeutic option for preventing or treating these 409 conditions. Further researches including large scale clinical trials and mechanisms 410 researches are needed to explore the complex interplay between RAS system and skin 411 fibrosis and the potential appications of RAS system on skin fibrotic diseases.

- 412
- 413 Reference
- 414 1. Jeschke MG, Wood FM, Middelkoop E, et al. Scars. Nat Rev Dis Primers.
- 415 2023;9(1):64. Published 2023 Nov 16. doi:10.1038/s41572-023-00474-x
- 416 2. Ung CY, Warwick A, Onoufriadis A, et al. Comorbidities of Keloid and
 417 Hypertrophic Scars Among Participants in UK Biobank. *JAMA Dermatol.*
- 418 2023;159(2):172-181. doi:10.1001/jamadermatol.2022.5607
- 419 3. Deng CC, Hu YF, Zhu DH, et al. Single-cell RNA-seq reveals fibroblast

- 420 heterogeneity and increased mesenchymal fibroblasts in human fibrotic skin
- 421 diseases. Nat Commun. 2021;12(1):3709. Published 2021 Jun 17.
- 422 doi:10.1038/s41467-021-24110-y
- 423 4. Lopez-Sublet M, Caratti di Lanzacco L, Danser AHJ, Lambert M, Elourimi G, Persu
- 424 A. Focus on increased serum angiotensin-converting enzyme level: From
- 425 granulomatous diseases to genetic mutations. *Clin Biochem.* 2018;59:1-8.
- 426 doi:10.1016/j.clinbiochem.2018.06.010
- 427 5. Zheng C, Huang L, Luo W, et al. Inhibition of STAT3 in tubular epithelial cells
- 428 prevents kidney fibrosis and nephropathy in STZ-induced diabetic mice. *Cell Death*
- 429 Dis. 2019;10(11):848. Published 2019 Nov 7. doi:10.1038/s41419-019-2085-0
- 6. Russo V, Papa AA, Williams EA, et al. ACE inhibition to slow progression of
 myocardial fibrosis in muscular dystrophies. *Trends Cardiovasc Med.*2018;28(5):330-337. doi:10.1016/j.tcm.2017.12.006
- 7. Shim KY, Eom YW, Kim MY, Kang SH, Baik SK. Role of the renin-angiotensin
 system in hepatic fibrosis and portal hypertension. *Korean J Intern Med.*2018;33(3):453-461. doi:10.3904/kjim.2017.317
- 436 8. Li S, Zhao W, Tao Y, Liu C. Fugan Wan alleviates hepatic fibrosis by inhibiting
- 437 ACE/Ang II/AT-1R signaling pathway and enhancing ACE2/Ang 1-7/Mas signaling
- 438 pathway in hepatic fibrosis rat models. Am J Transl Res. 2020;12(2):592-601.
- 439 Published 2020 Feb 15.
- 440 9. Feng J, Huang X, Xu Q, et al. Pharmacological inhibition of the ACE/Ang-2/AT1
- 441 axis alleviates mechanical ventilation-induced pulmonary fibrosis. Int
- 442 *Immunopharmacol.* 2024;131:111855. doi:10.1016/j.intimp.2024.111855
- 443 10. Souza-Silva IM, Steckelings UM, Assersen KB. The role of vasoactive peptides in
- skin homeostasis-focus on adiponectin and the kallikrein-kinin system. Am J Physiol
- 445 *Cell Physiol*. 2023;324(3):C741-C756. doi:10.1152/ajpcell.00269.2022
- 446 11. Fang QQ, Wang XF, Zhao WY, et al. The source of ACE during scar formation is
- 447 from both bone marrow and skin tissue. FASEB J. 2018;32(9):5199-5208.
- 448 doi:10.1096/fj.201701575RRR
- 449 12. Rha EY, Kim JW, Kim JH, Yoo G. Angiotensin-Converting Enzyme Inhibitor,

450 Captopril, Improves Scar Healing in Hypertensive Rats. *Int J Med Sci.*451 2021;18(4):975-983. Published 2021 Jan 1. doi:10.7150/ijms.50197

- 452 13. Demir CY, Ersoz ME, Erten R, Kocak OF, Sultanoglu Y, Basbugan Y. Comparison
- 453 of Enalapril, Candesartan and Intralesional Triamcinolone in Reducing Hypertrophic
- 454 Scar Development: An Experimental Study. *Aesthetic Plast Surg.* 2018;42(2):352-361.
- 455 doi:10.1007/s00266-018-1073-6
- 456 14. Dow T, Selman T, Williams J, Bezuhly M. The Role of ACE-Inhibitors and ARBs
- 457 in reducing hypertrophic scarring following bilateral breast reduction. J Plast
- 458 *Reconstr Aesthet Surg.* 2023;78:1-3. doi:10.1016/j.bjps.2022.11.032
- 459 15. Mohammadi AA, Parand A, Kardeh S, Janati M, Mohammadi S. Efficacy of
- 460 Topical Enalapril in Treatment of Hypertrophic Scars. World J Plast Surg.
- 461 2018;7(3):326-331. doi:10.29252/wjps.7.3.326
- 462 16. Greif T, Alsawas M, Reid AT, et al. Targeting the Angiotensin Pathway in the
- 463 Treatment of Cutaneous Fibrosis: A Systematic Review. *JID Innov.* 2023;3(6):100231.
- 464 Published 2023 Sep 12. doi:10.1016/j.xjidi.2023.100231
- 465 17. Bowden J, Holmes MV. Meta-analysis and Mendelian randomization: A review.
- 466 *Res Synth Methods*. Dec 2019;10(4):486-496. doi:10.1002/jrsm.1346
- 467 18. Lanlan Chen, Stephen Burgess, Shan Luo, Guoyue Lv First release of Mendelian
- 468 randomisation book in Chinese: eGastroenterology 2023;1:e100043.
- 469 19. Noishiki C, Hayasaka Y, Yoshida R, Ogawa R. Over 90% of Childhood BCG
- 470 Vaccine-Induced Keloids in Japan Occur in Women. Dermatol Ther (Heidelb).
- 471 2023;13(5):1137-1147. doi:10.1007/s13555-023-00916-0
- 472 20. Arima J, Huang C, Rosner B, Akaishi S, Ogawa R. Hypertension: a systemic key
- 473 to understanding local keloid severity. Wound Repair Regen. 2015;23(2):213-221.
- 474 doi:10.1111/wrr.12277
- 475 21. Lanlan Chen, Guoyue Lv New horizons of human genetics in digestive
 476 diseases: eGastroenterology 2023;1:e100029.
- 477 22. Eldjarn GH, Ferkingstad E, Lund SH, et al. Large-scale plasma proteomics
 478 comparisons through genetics and disease associations. *Nature*.
 479 2023;622(7982):348-358. doi:10.1038/s41586-023-06563-x

480 23. Abdollahi MR, Huang S, Rodriguez S, et al. Homogeneous assay of rs4343, an

- 481 ACE I/D proxy, and an analysis in the British Women's Heart and Health Study
- 482 (BWHHS). Dis Markers. 2008;24(1):11-17. doi:10.1155/2008/813679
- 483 24. Yarmolinsky J, Díez-Obrero V, Richardson TG, et al. Genetically proxied
- 484 therapeutic inhibition of antihypertensive drug targets and risk of common cancers: A
- 485 mendelian randomization analysis. *PLoS Med.* 2022;19(2):e1003897. Published 2022
- 486 Feb 3. doi:10.1371/journal.pmed.1003897
- 487 25. Kehoe PG, Katzov H, Andreasen N, et al. Common variants of ACE contribute to
- 488 variable age-at-onset of Alzheimer's disease. *Hum Genet*. 2004;114(5):478-483.
 489 doi:10.1007/s00439-004-1093-y
- 490 26. Gill D, Georgakis MK, Koskeridis F, et al. Use of Genetic Variants Related to
 491 Antihypertensive Drugs to Inform on Efficacy and Side Effects. *Circulation*.
 492 2019;140(4):270-279. doi:10.1161/CIRCULATIONAHA.118.038814
- 493 27. Hanchen Liu, Xiaoxi Zhang, Yu Zhou, Thanh N Nguyen, Lei Zhang, Pengfei Xing,
- Zifu Li, Hongjian Shen, Yongxin Zhang, Weilong Hua, Hongye Xu, Xuan Zhu, Lei
 Chen, Qiao Zuo, Rui Zhao, Qiang Li, Dongwei Dai, Yongwei Zhang, Yi Xu, Qinghai
 Huang, Jianmin Liu, Pengfei Yang, Association between blood pressure and different
 antihypertensive drugs with outcome after ischemic stroke: A Mendelian
 randomization study. *International Journal of Stroke*. 2023; 18(10): 1247-1254, doi:
 10.1177/17474930231185695
- 500 28. Loh PR, Kichaev G, Gazal S, Schoech AP, Price AL. Mixed-model association for
- 501
 biobank-scale
 datasets. Nat
 Genet.
 2018;50(7):906-908.

 502
 doi:10.1038/s41588-018-0144-6
- 503 29. GTEx Consortium. The GTEx Consortium atlas of genetic regulatory effects
- 504 across human tissues. *Science*. 2020;369(6509):1318-1330.
- 505 doi:10.1126/science.aaz1776
- 506 30. Kurki MI, Karjalainen J, Palta P, et al. FinnGen provides genetic insights from a
- 507 well-phenotyped isolated population [published correction appears in Nature. 2023
- 508 Feb 24;:]. Nature. 2023;613(7944):508-518. doi:10.1038/s41586-022-05473-8
- 509 31. Fairley S, Lowy-Gallego E, Perry E, Flicek P. The International Genome Sample

510 Resource (IGSR) collection of open human genomic variation resources. Nucleic

511 Acids Res. 2020;48(D1):D941-D947. doi:10.1093/nar/gkz836

512 32. Yao S, Zhang M, Dong SS, et al. Bidirectional two-sample Mendelian
513 randomization analysis identifies causal associations between relative carbohydrate
514 intake and depression. *Nat Hum Behav.* 2022;6(11):1569-1576.
515 doi:10.1038/s41562-022-01412-9

- 516 33. Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with
- 517 multiple genetic variants using summarized data. *Genet Epidemiol*. Nov 518 2013;37(7):658-65. doi:10.1002/gepi.21758
- 519 34. Hemani G, Zheng J, Elsworth B, et al. The MR-Base platform supports systematic
- 520 causal inference across the human phenome. *Elife*. 2018;7:e34408. Published 2018
- 521 May 30. doi:10.7554/eLife.34408
- 522 35. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in
- 523 Mendelian Randomization with Some Invalid Instruments Using a Weighted Median
- 524 Estimator. *Genet Epidemiol*. May 2016;40(4):304-14. doi:10.1002/gepi.21965
- 525 36. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid
 526 instruments: effect estimation and bias detection through Egger regression. *Int J*527 *Epidemiol.* Apr 2015;44(2):512-25. doi:10.1093/ije/dyv080
- 528 37. Yao S, Zhang M, Dong SS, et al. Bidirectional two-sample Mendelian
- 529 randomization analysis identifies causal associations between relative carbohydrate
- 530 intake and depression. *Nat Hum Behav.* 2022;6(11):1569-1576.
- 531 doi:10.1038/s41562-022-01412-9
- 532 38. Stephen Burgess, Héléne Toinét Cronjé Incorporating biological and clinical
 533 insights into variant choice for Mendelian randomisation: examples and
 534 principles: eGastroenterology 2024;2:e100042.
- 535 39. Burgess S, Thompson SG. Avoiding bias from weak instruments in Mendelian
 536 randomization studies. *Int J Epidemiol.* Jun 2011;40(3):755-64.
 537 doi:10.1093/ije/dyr036
- 538 40. Burgess S. Sample size and power calculations in Mendelian randomization with a
 539 single instrumental variable and a binary outcome. *Int J Epidemiol.* Jun

- 540 2014;43(3):922-9. doi:10.1093/ije/dyu005
- 541 41. Zhu Z, Zhang F, Hu H, et al. Integration of summary data from GWAS and eQTL
- studies predicts complex trait gene targets. *Nat Genet*. 2016; 48 (5):481-487.
 doi:10.1038/ng.3538
- 544 42. Hedayatyanfard K, Ziai SA, Niazi F, Habibi I, Habibi B, Moravvej H. Losartan
- 545 ointment relieves hypertrophic scars and keloid: A pilot study. Wound Repair Regen.
- 546 2018; 26 (4):340-343. doi:10.1111/wrr.12648
- 43. Ardekani GS, Aghaie S, Nemati MH, Handjani F, Kasraee B. Treatment of a
 postburn keloid scar with topical captopril: report of the first case [published
 correction appears in Plast Reconstr Surg. 2009 Jun;123(6):1898. Aghaie, Shahin
 [corrected to Aghaei, Shahin]]. *Plast Reconstr Surg.* 2009; 123 (3):112e-113e.
 doi:10.1097/PRS.0b013e31819a34db
- 552 44. Silva IMS, Assersen KB, Willadsen NN, Jepsen J, Artuc M, Steckelings UM. The
- role of the renin-angiotensin system in skin physiology and pathophysiology. *Exp Dermatol.* 2020;29(9):891-901. doi:10.1111/exd.14159
- 555 45. Hedayatyanfard K, Haddadi NS, Ziai SA, et al. The renin-angiotensin system in
- cutaneous hypertrophic scar and keloid formation. *Exp Dermatol*. 2020;29(9):902-909.
- 557 doi:10.1111/exd.14154
- 558 46. Fagerberg L, Hallström BM, Oksvold P, et al. Analysis of the human 559 tissue-specific expression by genome-wide integration of transcriptomics and
- 560 antibody-based proteomics. Mol Cell Proteomics. 2014; 13 (2):397-406.
- 561 doi:10.1074/mcp.M113.035600

IV	Exposur	NSN	\mathbf{P}^2	F	Sampl	Populatio	Sourc
IV	es	Р	К	Г	e size	n	e
serum_AC E	Serum ACE	30	0.24	376.28	35275	EUR	pQTL of Icelan d corhor t
ACE_SBP	ACE effect on SBP	2	6.47e-0 5	30.38	46976 7	EUR	UKB
ACE_DBP	ACE effect on DBP	2	6.43e-0 5	31.53	49046 9	EUR	UKB
serum_AC Ei	Serum ACE inhibitio n	14	0.34-0.3 9	2156.5-2594 .9	4174	EUR	pQTL of GER A
ACEi_SBP	ACE inhibitio n effect on SBP	2	0.28	759.90	75760 1	EUR	UKB and ICBP
SBP	SBP	293	4.37e-0 2	76.66	46976 7	EUR	UKB
DBP	DBP	283	4.56e-0 2	85.79	49046 9	EUR	UKB
Rs4291	ACE inhibitio	1	3.69e-0 4	276.00	74528 0	EUR	UKB and

Table 1 Detailed Information for Exposure GWAS Data

	n effect						ICBP
	on SBP						
	BB		2540.0		72800		UKB
BB	effect on	6	4	188.00	73000 2	EUR	and
	SBP				2		ICBP
	CCB		5 260 0		72650		UKB
CCB	effect on	24	3.20e-0	176.32	/3030 o	EUR	and
	SBP		3		ð		ICBP
	ARB		2.00- 0		75760		UKB
ARB	effect on	1	5.99e-0	30.25	15/00	EUR	and
	SBP		3		1		ICBP

GERA: Genetic Epidemiology Research on Adult Health and Aging

ICBP: International Consortium of Blood Pressure-Genome Wide Association Studies

Phenotype	UKB-id	Sample	Ncase	Ncontrol	Source	Population	
Thenotype		size	reuse	reolition	bource		
Hypertrophic scar	-	323,197	1294	321903	Finngen	EUR	
Keloid	701.4	404,486	216	402139	UKB	EUR	
Skin fibrosis and scar	701.2	101 196	2245	402141	UVD	EUD	
condition	/01.2	404,480	2545	402141	UND	EUK	
Skin fibrosis and scar		222 704	<u>901</u>	221002	Einnaan	EUD	
condition	-	322,794	071	521905	riingen	EUK	

IV	Expo sure	Outco me	Pleiotr opy	Heterog eneity	Meth od	Bet a	SE	P-v alue	OR (95%CI)
rs4343 rs4343	Seru m ACE inhibi tion Seru m ACE inhibi	Hypert rophic Scar (FinnG en) Keloid (UKB)	NA	NA	Wald ratio Wald ratio	0.04 36 0.11 59	0.0 591 0.1 540	0.46 07 0.45 17	1.0446 (0.9303- 1.1729) 1.1229 (0.8304- 1.5184)
rs4343	tion Seru m ACE inhibi tion	Skin Fibrosi s and Scar Conditi on (UKB)	NA	NA	Wald ratio	-0.0 476	0.0 460	0.30 09	0.9535 (0.8712- 1.0435)
rs4343	Seru m ACE inhibi tion	Skin Fibrosi s and Scar Conditi on (FinnG en)	NA	NA	Wald ratio	-0.0 747	0.0 708	0.29 16	0.928 (0.8077- 1.0662)

Table 3 Serum ACE and Skin Fibrotic Diseases

		Hypert							
serum_ ACE	Seru m ACE	rophic Scar (FinnG	0.8122	0.4179	IVW- FE	-0.0 412	0.0 538	0.44 36	0.9596 (0.8636- 1.0663)
					IVW- MRE Weig hted Media	-0.0 412 0.02 56	0.0 546 0.0 765	0.45 07 0.73 75	0.9596 (0.8622- 1.0681) 1.026 (0.8831- 1.192)
					n Simpl e Mode Weig	0.06 95	0.1 245	0.58 08	1.072 (0.8399- 1.3682) 1.0147
	-				hted Mode	46	732	30	(0.8792- 1.1712)
serum_ ACE	m ACE	Keloid (UKB)	0.8346	0.9486	IVW- FE	0.02 72	0.1 387	0.84 43	1.0276 (0.783-1. 3487)
					IVW- MRE	0.02 72	0.1 086	0.80 20	1.0276 (0.8306- 1.2714)
					Weig hted Media n	0.13 08	0.1 899	0.49 09	1.1397 (0.7855- 1.6536)
					Simpl	-0.1	0.3	0.71	0.881

					e	267	449	61	(0.4481-
					Mode				1.7322)
					Weig	0.10	0.1	0.58	1.1161
					hted	0.10	0.1	0.38 45	(0.7563-
					Mode	90	980	45	1.6471)
		Skin							
		Fibrosi							
aamim	Seru	s and	0.5314			0.0	0.0	0.55	0.9757
	m	Scar	0.5514	0.5025		-0.0	0.0 420	0.55	(0.8986-
ACE	ACE	Conditi			ГĽ	240	420	15	1.0594)
		on							
		(UKB)							
					IV/W/	0.0	0.0	0.55	0.9757
						-0.0	415	0.55	(0.8995-
					WINL	240	415	20	1.0583)
					Weig				0 0280
					hted	-0.0	0.0	0.20	(0.8202
					Media	738	579	31	1.0406)
					n				1.0400)
					Simpl	0.0	0.0	0.63	0.9564
					e	-0.0	0.0	0.05	(0.7974-
					Mode	440)20		1.1471)
					Weig	0.0	0.0	0.25	0.9332
					hted	-0.0	500	0.25	(0.8312-
					Mode	072	570	0)	1.0476)
	Seru	Skin							1 1055
serum_	m	Fibrosi	0 4761	0 9259	IVW-	0.10	0.0	0.11	(0.9747-
ACE	ACF	s and	0.7701	0.7437	FE	03	643	85	1 2530
	ACE	Scar							1.2337)

C 1:4:	
1 000/01111	
• • • • • • • • • •	

on

(FinnG

en)

									1.1055
					IVW-	0.10	0.0	0.05	(0.9989-
					MRE	03	518	26	1 2236)
					W /-:-				1.2250)
					Weig				1.0589
					hted	0.05	0.0	0.50	(0.8939-
					Media	72	864	78	1.2544)
					n				1.2011)
					Simpl	0.0	0.1	0.02	0.9886
					e	-0.0	0.1	0.93	(0.7637-
					Mode	115	317	12	1.2797)
					Weig				1.0422
					hted	0.04	0.0	0.62	(0.8844-
					Mode	13	838	56	1.2282)
	Seru	Hypert							,
	m	rophia							0.0091
serum_		ropine	0 (00 (0 4511	IVW-	-0.0	0.0	0.96	0.9901
ACEi	ACE	Scar	0.6886	0.4511	FE	019	394	07	(0.9238-
	inhibi	(FinnG							1.0783)
	tion	en)							
						0.0	0.0	0.06	0.9981
					1 0 00-	-0.0	0.0	0.90	(0.924-1.
					MRE	019	393	06	078)
					Weig				
					hted	-0.0	0.0	0.69	0.9803
					Media	199	504	32	(0.8881-
					n				1.0821)
					11				

	G				Simpl e Mode Weig hted Mode	-0.1 264 0.01 41	0.0 872 0.0 555	0.17 26 0.80 37	0.8812 (0.7428- 1.0454) 1.0142 (0.9097- 1.1307)
serum_ ACEi	m ACE inhibi tion	Keloid (UKB)	0.6304	0.6612	IVW- FE	0.04 65	0.1 064	0.66 24	1.0476 (0.8503- 1.2906)
					IVW- MRE	0.04 65	0.0 952	0.62 54	1.0476 (0.8693- 1.2625)
					Weig hted Media n	0.11 24	0.1 331	0.39 87	1.1189 (0.8619- 1.4525)
					Simpl e Mode	0.02 73	0.2 310	0.90 77	1.0277 (0.6535- 1.6163)
	2	a 1.			Weig hted Mode	0.11 30	0.1 456	0.45 14	1.1197 (0.8417- 1.4894)
serum_ ACEi	m ACE inhibi tion	Skin Fibrosi s and Scar Conditi	0.6263 33556	0.13664 7881	IVW- FE	-0.0 311	0.0 321	0.33 21	0.9693 (0.9102- 1.0323)

on

(UKB)

					IV/W/	0.0	0.0	0.41	0.9693
						-0.0	201	72	(0.8991-
					WIKE	511	304	12	1.0451)
					Weig hted Media n Simpl e Mode Weig hted Mode	-0.0 387 0.05 18 -0.0 386	0.0 405 0.0 938 0.0 443	0.33 95 0.59 02 0.39 96	0.9621 (0.8887- 1.0415) 1.0531 (0.8763- 1.2656) 0.9622 (0.8821- 1.0494)
serum_ ACEi	Seru m ACE inhibi tion	Skin Fibrosi s and Scar Conditi on (FinnG en)	0.1366	0.7004	IVW- FE	-0.0 661	0.0 473	0.16 21	0.9361 (0.8532- 1.0269)
					IVW- MRE Weig	-0.0 661 -0.0	0.0 410 0.0	0.10 70 0.32	0.9361 (0.8638- 1.0144) 0.9419
					Media	599	603	08	1.0601)

n				
Simpl	0.01	0.1	0.00	1.0135
e	0.01	0.1	0.89	(0.8311-
Mode	34	012	70	1.2358)
Weig				0.9581
hted	-0.0	0.0	0.51	(0.8452-
Mada	428	640	67	1.09(2)
Mode				1.0862)

TX 7	Expo	Outco	Pleiot	Hetero	Meth	Bet	(TE	P-v	OR
IV	sure	me	ropy	geneity	od	a	SE	alue	(95%CI)
rs429 1	Effec t of ACE inhib ition on SBP	Hypert rophic Scar (FinnG en)	NA	NA	Wald ratio	0.0 717	0.1 338	0.59 22	1.0743 (0.8264-1.3 965)
rs429 1	Effec t of ACE inhib ition on SBP	Skin Fibrosi s and Scar Conditi on (FinnG en)	NA	NA	Wald ratio	0.1 193	0.1 604	0.45 68	1.1268 (0.8228-1.5 429)
ACE_ SBP	Effec t of ACE on SBP	Hypert rophic Scar (FinnG en)	NA	NA	Wald ratio	1.7 460	3.1 452	0.57 88	5.7315 (0.0121-272 5.9807)
ACE_ SBP	Effec t of ACE on SBP	Skin Fibrosi s and Scar Conditi on	NA	NA	Wald ratio	5.1 906	3.7 723	0.16 88	179.5763 (0.1105-291 939.3434)

Table 4 ACE Effect on Blood Pressure and Skin Fibrotic Diseases

		(FinnG							
		en)							
	Effec	Hypert							
ΔCF	t of	rophic			Wald	17	3.1	0.57	5.7621
DRP	ACE	Scar	NA	NA	ratio	513	5/18	88	(0.0119-279
DDI	on	(FinnG			Tatio	515	5-0	00	2.3439)
	DBP	en)							
		Skin							
	Effec	Fibrosi							
	t of	s and							182.433
ACE_	ACE	Scar	NA	NA	Wald	5.2	3.7	0.16	(0.1097-303
DBP	on	Conditi			ratio	064	838	88	326.6091)
	DBP	on							
		(FinnG							
		en)							
	Effec								
	t of	Hypert							
ACEi	ACE	rophic			IVW-	0.0	0.1	0.44	1.0948
_SBP	inhib	Scar	NA	0.8594	FE	905	192	75	(0.8667-1.3
	ition	(FinnG							829)
	on	en)							
	SBP								1.0040
					IVW-	0.0	0.0	0.00	1.0948
					MRE	905	211	00	(1.0504-1.1
	Fffoo	Skin							41)
ACE	tof	Fibrosi			IV/W/	0.2	0.1	0.14	1.2292
SRD		s and	NA	0.4739	EE 1 4 44-	0.2	0.1 مرم	9.14 88	(0.9289-1.6
יחפ"	inhib	s anu Scar			ГĽ	005	427	00	265)
	mmu	Scal							

ition	Conditi						
on	on						
SBP	(FinnG						
	en)						
			TX 7 XX 7	0.0	0.1	0.04	1.2292
			1 V W -	0.2	0.1	0.04	(1.0057-1.5
			MRE	063	023	38	(1.0007 1.0
							022)

	Outco	Ge	Probe	Тор	А	А	Fr	B_s	Se	P_s	P_h	NSNP
Tissue	me	ne	_bp	snp	1	2	eq	mr	smr	mr	eidi	heidi –
Supra pubic skin	Hypetr ophic scar	A CE	6155 4422	Rs4 311	С	Т	0. 50	-0.1 3	0.23	0.5 8	0.77	8
Supra pubic skin	Keloid	A CE	6155 4422	Rs4 311	С	Т	0. 50	-0.6 3	0.62	0.3 1	0.95	8
Supra pubic skin	Skin fibrosis and scar conditi on (UKB)	A CE	6155 4422	Rs4 311	С	Т	0. 50	0.0 6	0.18	0.7 6	0.47	8
Supra pubic skin	Skin fibrosis and scar conditi on (Finng en)	A CE	6155 4422	Rs4 311	С	Т	0. 50	0.1 8	0.28	0.5	0.88	8
Leg	Hypetr ophic scar	A CE	6155 4422	Rs4 292	Т	C	0. 63	0.1 4	0.21	0.5 0	0.22	11
Leg	Keloid	A CE	6155 4422	Rs4 292	Т	C	0. 63	-0.3 6	0.55	0.5 2	1.00	11

Table 5 ACE Expression in Local Skin Tissue and Skin Fibrotic Diseases

	Skin											
	fibrosis											
	and		(155	D - 4			0	0.0		0.0		
Leg	scar	А	0155	RS4	Т	С	0.	0.0	0.17	0.9	0.35	11
	conditi	CE	4422	292			63	2		0		
	on											
	(UKB)											
	Skin											
	fibrosis											
	and											
т	scar	А	6155	Rs4	т	C	0.	0.1	0.25	0.4	0.05	11
Leg	conditi	CE	4422	292	1	C	63	8	0.25	7	0.95	11
	on											
	(Finng											
	en)											

			neurog	Metho	Dati	CE	P-va	OR
sure	me	ropy	eneity	d	Beta	SE	lue	(95%CI)
SBP	Hypertr ophic Scar	0.2526	0.0588	IVW-	-0.3	0.1	0.00	0.6925 (0.54-0.8
	(FinnGe			FE	675	269	38	881)
	n)							
				IVW- MRE	-0.3 675	0.1 353	0.00 66	0.6925 (0.5312-0 .9028)
				Weigh				0 (001
				ted	-0.3	0.2	0.08	0.6981
				Media	594	090	55	(0.4635-1
				n				.0515)
				Simple Mode	-0.6 215	0.6 273	0.32 27	0.5372 (0.1571-1
				Weigh ted Mode	-0.4 694	0.4 676	0.31 63	.8368) 0.6254 (0.2501-1 .5637)
	Skin							
	Fibrosis and							
SBP	Scar Conditi on (FinnGe n)	0.1628	0.6433	IVW- FE	-0.1 106	0.1 519	0.46 65	0.8953 (0.6647-1 .2058)
	SBP	Sure Inc Sure Ophic ophic Sure Ophic (FinnGe n) Sure	Sint Hypertri ophic 0.2526 (FinnGe) 0.2526 n) 1 n) 1 Siman (Siman) 1	sure int topy citcury Hypertir ophic	sint int ropy earry c Hypertr ophic SBP Scar 0.2526 0.0588 FE (FinnGe n) IVW- FE IVW- MRE Weigh ted Media n Simple Mode Simple Mode Keigh ted Mode Simple Mode FE Node Node Simple Mode FE Mode FE Mode FE Mode FE FE FE FE FE FE FE FE FE FE	site int ropy curry c Hypertr ophic 0.2526 0.0588 IVW- -0.3 SBP Scar 0.2526 0.0588 FE 675 (FinnGe n) IVW- -0.3 FE 675 n) IVW- -0.3 MRE 675 Weigh 40 -0.3 MRE 675 Weigh ted -0.3 MRE 594 n Veigh ted -0.3 Media 594 n -0.6 Mode 215 Media 594 n Veigh -0.4 694 Mode 215 Skin Kin Kin Fibrosis and Keigh SBP Scar 0.1628 0.6433 N 0.6433 FE 106 N infield infield infield	sint ropy currenty currenty currenty currenty currenty currenty ophic subscript of the state	and ropy curry a rac and Hypertr ophic 1VW- -0.3 0.1 0.00 SBP Scar 0.2526 0.0588 IVW- 675 269 38 n) IVW- -0.3 0.1 0.00 ME 675 353 66 m) IVW- -0.3 0.1 0.00 MRE 675 353 66 Weigh ted -0.3 0.2 0.08 Media 594 090 55 n Simple -0.6 0.6 0.32 0.08 Media 594 090 55 n - - Kin Fibrosis Simple -0.6 0.6 0.32 - Mode 215 273 27 - - - - - - SBP Skin - - - - - - - - -<

Table 6 Blood Pressure and Skin Fibrotic Diseases

									0.8953
					IVW-	-0.1	0.1	0.45	(0.6681-1
					MRE	106	494	89	.1998)
					Weigh				0.8835
					ted	-0.1	0.2	0.61	(0.5459-1
					Media	238	456	42	(0.0 10) 1
					n				
					Simple	0.03	0.6	0.95	1.0375
					Mode	60	428	12	(0.2944-3
					Mode	09	420	45	.6571)
					Weigh	0.2	0.4	0.61	0.7902
					ted	-0.2	0.4	17	(0.3186-1
					Mode	555	034	17	.9598)
		Hypertr							
D		ophic			TX / XX /	0.0	0.1	0.50	0.9366
D	DBP	Scar	0.1156	0.0278	IVW-	-0.0	0.1	0.59	(0.7354-1
ΒΡ		(FinnGe			FE	655	234	55	.1928)
		n)							
						0.0	0.4	0	0.9366
					IVW-	-0.0	0.1	0.62	(0.721-1.
					MRE	655	335	36	2167)
					Weigh				
					ted	-0.1	0.1	0.39	0.8455
					Media	678	954	03	(0.5765-1
					n				.24)
								_	0.7188
					Simple	-0.3	0.5	0.57	(0.2273-2
					Mode	302	873	44	.2724)
					Weigh	-0.1	0.4	0.64	0.8188

					ted	999	320	39	(0.3511-1
					Mode				.9096)
		Skin							
		Fibrosis							
		and							0 9721
D	DRP	Scar	0 9617	0 7486	IVW-	-0.0	0.1	0.84	(0.7277_{-1})
BP	DDI	Conditi	0.9017	0.7400	FE	283	477	79	(0.7277 1
		on							,,
		(FinnGe							
		n)							
					IV/W/	0.0	0.1	0.84	0.9721
					1 v w-	-0.0	0.1	0.04	(0.734-1.
					MRE	283	433	33	2873)
					Weigh				0.0065
					ted	-0.0	0.2	0.68	0.9065
					Media	982	395	19	(0.3009-1
					n				.4495)
					Q' 1	0.1	0.6	0.00	0.8547
					Simple	-0.1	0.6	0.80	(0.2394-3
					Mode	570	492	91	.0509)
					Weigh	0.2	0.4	0.54	0.7616
					ted	-0.2	0.4 401	0.54 17	(0.3159-1
					Mode	125	471	4/	.8365)

137	Expo	Outco	Pleiot	Heterog	Metho	Data	SE	P-va	OR
1 V	sure	me	ropy	eneity	d	Бега	SE	lue	(95%CI)
	Effect	Hypertr							
А	of	ophic			Wold	0.1	0.2	0.40	0.8603
R	ARBs	Scar	NA	NA	rotio	-0.1	200	40	(0.5589-1
В	on	(FinnGe			Tatio	303	200	40	.3241)
	SBP	n)							
		Skin							
	Dff	Fibrosis							
	Effect	and							1 2700
A	0I	Scar	NT A	NT A	Wald	0.32	0.2	0.22	1.3799
R	ARBS	Conditi	NA	NA	ratio	20	638	22	(0.8228-2
В	on	on							.3142)
	SBP	(FinnGe							
		n)							
	Effect	Hypertr							
D	of	ophic			TX 7XX 7	0.06	0.0	0.00	1.0648
В	BBs	Scar	0.4511	0.0085	IVW-	0.06	0.0	0.28	(0.9497-1
В	on	(FinnGe			FE	27	583	21	.1938)
	SBP	n)							
					** *** *	0.06	0.1	0.54	1.0648
					IVW-	0.06	0.1	0.54	(0.8706-1
					MRE	27	027	12	.3022)
					Weigh				1.01-5
					ted	0.01	0.0	0.84	1.0152
					Media	50	763	37	(0.8741-1
					n				.179)

Table 7 Other Antihypertension Drugs' Effect on Blood Pressure and Skin Fibrotic Diseases

		Skin			Simple Mode Weigh ted Mode	0.05 01 -0.0 226	0.1 072 0.0 822	0.65 98 0.79 47	1.0514 (0.8522-1 .2971) 0.9777 (0.8321-1 .1487)
B B	Effect of BBs on SBP	Fibrosis and Scar Conditi on (FinnGe n)	0.7791	0.6579	IVW- FE	0.16 88	0.0 696	0.01 53	1.1839 (1.033-1. 3569)
		,			IVW- MRE	0.16 88	0.0 563	0.00 27	1.1839 (1.0602-1 .3221)
					Weigh ted Media n	0.15 03	0.0 827	0.06 91	1.1622 (0.9883-1 .3667)
					Simple Mode	0.18 08	0.1 287	0.21 91	1.1982 (0.931-1. 5421)
					Weigh ted Mode	0.14 96	0.0 964	0.18 15	1.1614 (0.9614-1 .4031)
C C	Effect of	Hypertr ophic	0.3079	0.5962	IVW- FE	0.05 88	0.0 322	0.06 84	1.0605 (0.9956-1

В	CCBs	Scar							.1297)
	on	(FinnGe							
	SBP	n)							
					IVW- MRE	0.05 88	0.0 305	0.05 43	1.0605 (0.9989-1 .1259)
					Weigh ted Media n	0.06 93	0.0 447	0.12 12	1.0717 (0.9818-1 .1699)
		<u>61.:</u>			Simple Mode Weigh ted Mode	0.11 05 0.07 96	0.0 813 0.0 628	0.18 84 0.21 88	1.1168 (0.9524-1 .3097) 1.0829 (0.9574-1 .2248)
C C B	Effect of CCBs on SBP	Fibrosis and Scar Conditi on (FinnGe	0.7805	0.3859	IVW- FE	-0.0 556	0.0 386	0.14 99	0.946 (0.8771-1 .0203)
		n)			IVW- MRE Weigh ted	-0.0 556 -0.0 651	0.0 397 0.0 549	0.16 17 0.23 54	0.946 (0.8751-1 .0225) 0.937 (0.8415-1

Me	edia				.0433)
1	n				
Sin	nple -	-0.0	0.0	0.51	0.9456
M	ode f	559	850	81	(0.8005-1
				01	.1171)
We	eigh	0.0	0.0	0.28	0.9327
te	ed	-0.0	0.0	0.28	(0.8247-1
M	ode	090	028	00	.0549)



Exposure	Outcome	Method		OR(95% CI)	P.value
Serum ACE inhibition (rs4343)	Hypertrophic Scar (FinnGen)	Wald ratio	+	1.04 (0.93 to 1.17)	0.4607
Serum ACE inhibition (rs4343)	Keloid (UKB)	Wald ratio		1.12 (0.83 to 1.52)	0.4517
Serum ACE inhibition (rs4343)	Skin Fibrosis and Scar Condition (UKB)	Wald ratio	-	0.95 (0.87 to 1.04)	0.3009
Serum ACE inhibition (rs4343)	Skin Fibrosis and Scar Condition (FinnGen)	Wald ratio		0.93 (0.81 to 1.07)	0.2916
Serum ACE	Hypertrophic Scar (FinnGen)	IVW-FE	•	0.96 (0.86 to 1.07)	0.4436
		IVW-MRE	-	0.96 (0.86 to 1.07)	0.4507
Serum ACE	Keloid (UKB)	IVW-FE	_ #	1.03 (0.78 to 1.35)	0.8443
		IVW-MRE	_ #	1.03 (0.83 to 1.27)	0.8020
Serum ACE	Skin Fibrosis and Scar Condition (UKB)	IVW-FE	+	0.98 (0.90 to 1.06)	0.5575
		IVW-MRE	•	0.98 (0.90 to 1.06)	0.5526
Serum ACE	Skin Fibrosis and Scar Condition (FinnGen)	IVW-FE	-	1.11 (0.97 to 1.25)	0.1185
		IVW-MRE	-	1.11 (1.00 to 1.22)	0.0526
Serum ACE inhibition	Hypertrophic Scar (FinnGen)	IVW-FE	+	1.00 (0.92 to 1.08)	0.9607
		IVW-MRE	+	1.00 (0.92 to 1.08)	0.9606
Serum ACE inhibition	Keloid (UKB)	IVW-FE		1.05 (0.85 to 1.29)	0.6624
		IVW-MRE		1.05 (0.87 to 1.26)	0.6254
Serum ACE inhibition	Skin Fibrosis and Scar Condition (UKB)	IVW-FE	•	0.97 (0.91 to 1.03)	0.3321
		IVW-MRE	•	0.97 (0.90 to 1.05)	0.4172
Serum ACE inhibition	Skin Fibrosis and Scar Condition (FinnGen)	IVW-FE	-	0.94 (0.85 to 1.03)	0.1621
		IVW-MRE	-	0.94 (0.86 to 1.01)	0.1070
			0.5 1	2	
	←			>	

Less susceptible to diseases More susceptible to diseases

Exposure	Outcome	Method	OR(95% CI)	P.value
SBP	Hypertrophic Scar (FinnGen)	IVW-FE -	0.69 (0.54 to 0.89)	0.0038
		IVW-MRE -	0.69 (0.53 to 0.90)	0.0066
		MR Egger —	0.48 (0.24 to 0.95)	0.0352
		Weighted Median -	0.70 (0.46 to 1.05)	0.0855
		Simple Mode	0.54 (0.16 to 1.84)	0.3227
		Weighted Mode	0.63 (0.25 to 1.56)	0.3163
SBP	Skin Fibrosis and Scar Condition (FinnGen)	IVW-FE -	0.90 (0.66 to 1.21)	0.4665
		IVW-MRE -	0.90 (0.67 to 1.20)	0.4589
		MR Egger -	0.54 (0.25 to 1.16)	0.1167
		Weighted Median	0.88 (0.55 to 1.43)	0.6142
		Simple Mode	> 1.04 (0.29 to 3.66)	0.9543
		Weighted Mode	- 0.79 (0.32 to 1.96)	0.6117
DBP	Hypertrophic Scar (FinnGen)	IVW-FE -	0.94 (0.74 to 1.19)	0.5955
		IVW-MRE —	0.94 (0.72 to 1.22)	0.6236
		MR Egger -	0.58 (0.30 to 1.11)	0.1014
		Weighted Median -	0.85 (0.58 to 1.24)	0.3903
		Simple Mode =	> 0.72 (0.23 to 2.27)	0.5744
		Weighted Mode	0.82 (0.35 to 1.91)	0.6439
DBP	Skin Fibrosis and Scar Condition (FinnGen)	IVW-FE -	0.97 (0.73 to 1.30)	0.8479
		IVW-MRE -	0.97 (0.73 to 1.29)	0.8433
		MR Egger	- 0.96 (0.46 to 1.98)	0.9042
		Weighted Median -	0.91 (0.57 to 1.45)	0.6819
		Simple Mode	> 0.85 (0.24 to 3.05)	0.8091
		Weighted Mode 0.5 1	0.76 (0.32 to 1.84) 2	0.5447
		 Less susceptible to diseases 	eptible to diseases	

Drugs	Exposure	Outcome	Method		OR(95% CI)	P.value
ARB	Effect of ARBs on SBP	Hypertrophic Scar (FinnGen)	Wald ratio —	■	0.86 (0.56 to 1.32)	0.4940
ARB	Effect of ARBs on SBP	Skin Fibrosis and Scar Condition (FinnGen)	Wald ratio		1.38 (0.82 to 2.31)	0.2222
BB	Effect of BBs on SBP	Hypertrophic Scar (FinnGen)	IVW-FE	-	1.06 (0.95 to 1.19)	0.2821
			IVW-MRE		1.06 (0.87 to 1.30)	0.5412
			Weighted Median	+	1.02 (0.87 to 1.18)	0.8437
			Simple Mode		1.05 (0.85 to 1.30)	0.6598
			Weighted Mode	-	0.98 (0.83 to 1.15)	0.7947
BB	Effect of BBs on SBP	Skin Fibrosis and Scar Condition (FinnGen)	IVW-FE		1.18 (1.03 to 1.36)	0.0153
			IVW-MRE		1.18 (1.06 to 1.32)	0.0027
			Weighted Median		1.16 (0.99 to 1.37)	0.0691
			Simple Mode		1.20 (0.93 to 1.54)	0.2191
			Weighted Mode	⊢∎	1.16 (0.96 to 1.40)	0.1815
ССВ	Effect of CCBs on SBP	Hypertrophic Scar (FinnGen)	IVW-FE	•	1.06 (1.00 to 1.13)	0.0684
			IVW-MRE	•	1.06 (1.00 to 1.13)	0.0543
			Weighted Median	-	1.07 (0.98 to 1.17)	0.1212
			Simple Mode		1.12 (0.95 to 1.31)	0.1884
			Weighted Mode		1.08 (0.96 to 1.22)	0.2188
CCB	Effect of CCBs on SBP	Skin Fibrosis and Scar Condition (FinnGen)	IVW-FE	-	0.95 (0.88 to 1.02)	0.1499
			IVW-MRE	-	0.95 (0.88 to 1.02)	0.1617
			Weighted Median	•	0.94 (0.84 to 1.04)	0.2354
			Simple Mode	-	0.95 (0.80 to 1.12)	0.5181
			Weighted Mode	•	0.93 (0.82 to 1.05) 1 2	0.2800
			←		\longrightarrow	

Less susceptible to diseases More susceptible to diseases